Table 4.

Incidence of other side effects in studies of selective COX2 inhibitors

Study (reference)	Drugs	Side effects Renal	Edema	Blood pressure		Hypertension	CHF	Hepatic ALT+AST+		Cutaneous reactions
		Creat+v		systolic	diastolic
VIGOR (Bombardier 2000)	Rofecoxib	1.2%	nr	nr	nr	nr	nr		nr	nr
	Naproxen	0.9%
CLASS (Silverstein 2000)	Celecoxib	0.7%*	2.8%	nr	nr	1.7%*	nr	0.6%*		7.5%*
	Diclofenac	1.2%	3.5%			2.3%		2.3%		4.1%
MEDAL (Cannon 2006; Laine 2007)	Etoricoxib	0.4%–2.3%	0.8%–1.9% (**at 90 mg)	nr	nr	2.2%–2.5% **	0.1%–0.7%	0.3%–0.4% **		nr
	Diclofenac	0.4 to 1.8%	0.4%–0.8%			0.7%–1.6%	0.1%–0.3%	1.5%–5.0%
TARGET (Schnitzer 2004; Farkouh 2004)	Lumiracoxib	***0.51%	nr	+0.4 mm§	−0.1 mm§	nr	0.24%	0.07%$$	2.57%$$$	nr
	Naproxen/Diclofenac	0.37%		+2.1 mm	+0.5 mm		0.34%	0.03%	0.63%

^*p < 0.05,

^§p < 0.0001 vs control drug.

^**p < 0.05 for discontinuations between treatment groups.

^***major renal events, NS.

^$$serious liver abnormalities (not further specified), NS.

^$$$transaminases >× 3 times upper normal limit, p < 0.0001.

Abbreviations: ALT+, elevated alanine aminotransferase; AST+, elevated aspartate aminotransferase; CHF, cardiac heart failure; nr, not reported.